The European Commission (EC) has granted conditional marketing authorization for gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene).
It is indicated for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.
The drug’s developer, USA-based bluebird bio (Nasdaq: BLUE) - whose share rose as much as 4% on the news, says it will continue the country-by-country reimbursement process to help ensure access to Zynteglo (previously known as LentiGlobin) for appropriate patients in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze